Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) has been given a consensus rating of “Hold” by the twelve analysts that are presently covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, seven have given a hold rating and four have issued a buy rating on the company. The average 1 year price target among brokerages that have issued ratings on the stock in the last year is $18.13.
IRWD has been the topic of several research reports. Mizuho restated a “buy” rating and set a $22.00 price target on shares of Ironwood Pharmaceuticals in a research report on Sunday, July 23rd. BidaskClub upgraded Ironwood Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Friday, June 23rd. Wells Fargo & Company set a $19.00 price target on Ironwood Pharmaceuticals and gave the company a “buy” rating in a research report on Saturday, July 22nd. Cowen and Company set a $20.00 price target on Ironwood Pharmaceuticals and gave the company a “buy” rating in a research report on Friday, August 4th. Finally, Zacks Investment Research upgraded Ironwood Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research report on Monday, July 17th.
COPYRIGHT VIOLATION WARNING: This piece was published by StockNewsTimes and is owned by of StockNewsTimes. If you are viewing this piece on another website, it was illegally copied and reposted in violation of United States and international copyright & trademark laws. The original version of this piece can be accessed at https://stocknewstimes.com/2017/09/15/ironwood-pharmaceuticals-inc-irwd-receives-18-13-average-pt-from-brokerages.html.
Shares of Ironwood Pharmaceuticals (IRWD) traded up 1.25% during trading on Tuesday, hitting $16.24. The stock had a trading volume of 1,767,770 shares. The firm has a 50 day moving average price of $15.62 and a 200-day moving average price of $17.06. Ironwood Pharmaceuticals has a 52 week low of $12.48 and a 52 week high of $19.94. The stock’s market capitalization is $2.43 billion.
Ironwood Pharmaceuticals (NASDAQ:IRWD) last released its quarterly earnings results on Thursday, August 3rd. The biotechnology company reported ($0.28) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.23) by ($0.05). Ironwood Pharmaceuticals had a negative net margin of 52.97% and a negative return on equity of 333.83%. The firm had revenue of $65.10 million for the quarter, compared to the consensus estimate of $70.00 million. During the same quarter in the prior year, the firm earned ($0.16) earnings per share. The company’s revenue for the quarter was up 19.7% compared to the same quarter last year. On average, equities research analysts forecast that Ironwood Pharmaceuticals will post ($1.10) EPS for the current fiscal year.
In other Ironwood Pharmaceuticals news, insider Halley E. Gilbert sold 35,000 shares of Ironwood Pharmaceuticals stock in a transaction on Thursday, June 22nd. The stock was sold at an average price of $19.75, for a total transaction of $691,250.00. Following the completion of the transaction, the insider now owns 35,000 shares in the company, valued at $691,250. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders have sold 36,707 shares of company stock valued at $718,458 in the last quarter. 7.63% of the stock is owned by company insiders.
Large investors have recently made changes to their positions in the business. American Century Companies Inc. purchased a new position in Ironwood Pharmaceuticals during the first quarter valued at $1,879,000. Parametric Portfolio Associates LLC raised its stake in Ironwood Pharmaceuticals by 3.7% during the first quarter. Parametric Portfolio Associates LLC now owns 80,693 shares of the biotechnology company’s stock valued at $1,377,000 after buying an additional 2,913 shares during the last quarter. State of Wisconsin Investment Board raised its stake in Ironwood Pharmaceuticals by 148.4% during the second quarter. State of Wisconsin Investment Board now owns 621,000 shares of the biotechnology company’s stock valued at $11,724,000 after buying an additional 371,000 shares during the last quarter. Karp Capital Management Corp purchased a new position in Ironwood Pharmaceuticals during the first quarter valued at $201,000. Finally, Principal Financial Group Inc. raised its stake in Ironwood Pharmaceuticals by 0.3% during the first quarter. Principal Financial Group Inc. now owns 24,051 shares of the biotechnology company’s stock valued at $410,000 after buying an additional 62 shares during the last quarter. Institutional investors and hedge funds own 97.95% of the company’s stock.
About Ironwood Pharmaceuticals
Ironwood Pharmaceuticals, Inc is a biotechnology company. The Company is advancing product opportunities in areas of unmet need, including irritable bowel syndrome with constipation (IBS C), and chronic idiopathic constipation (CIC), hyperuricemia associated with uncontrolled gout, uncontrolled gastroesophageal reflux disease (uncontrolled GERD), and vascular and fibrotic diseases.
Receive News & Ratings for Ironwood Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ironwood Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.